Suven Life Sciences Q2 FY27 Results: Consolidated Net Loss ₹107 Crore on Total Income of ₹7.93 Crore
Suven Life Sciences (NSE: SUVEN) reported a consolidated total income of ₹7.93 crore and a consolidated net loss of ₹106.94 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. The standalone net loss for the quarter was ₹16.38 crore on the same total income of ₹7.93 crore.
- Earnings
- Biopharmaceutical drug discovery